Fulranumab

Summary

Fulranumab (CHEMBL1743023) is a phase-3 clinical-stage antibody; indicated across 5 conditions including osteoarthritis and diabetic neuropathy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743023
Name	Fulranumab
Type	Antibody
Max phase	3

Also known as: AMG 403, AMG-403, AMG403, Fulranumab, JNJ 42160443, JNJ-42160443, FULRANUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis	3	MONDO:0005178	MONDO:0005178
diabetic neuropathy	2	MONDO:0006626	EFO:1000783

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02289716	PHASE3	COMPLETED	Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
NCT02301234	PHASE3	COMPLETED	Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007
NCT02336685	PHASE3	COMPLETED	Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001
NCT02336698	PHASE3	COMPLETED	Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
NCT00929188	PHASE2	COMPLETED	A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
NCT00964990	PHASE2	TERMINATED	A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
NCT00973024	PHASE2	TERMINATED	A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
NCT00973141	PHASE2	TERMINATED	A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
NCT00993018	PHASE2	TERMINATED	A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
NCT01060254	PHASE2	TERMINATED	A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain
NCT01094262	PHASE2	TERMINATED	A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).